Manufacturing
U.S. Biotechs Reveal Tariff Exposure as Trade Inquiry Signals Imminent Pharmaceutical Tariffs
U.S. biotech, pharmaceutical tariffs, Section 232 investigation, supply chain exposure, trade policy, import costs, reshoring manufacturing, drug pricing, global supply chain, pharmaceutical ingredients, regulatory impact
Trump Tariffs Poised to Hit Drug Tool and Packaging Manufacturers: Industry Faces Rising Costs and Supply Chain Challenges
Trump tariffs , Drug packaging industry , Pharmaceutical supply chain , API manufacturing costs , Biopharma trade war , U.S. manufacturing onshoring , Generic drugs market impact , Pharmaceutical tariffs , Supply chain disruption , Pharmaceutical industry lobbying
Trump’s Looming Pharmaceutical Tariffs: Uncertainty and Potential Impact
Trump, pharmaceutical tariffs, trade policy, drug prices, manufacturing, supply chain
Johnson & Johnson Announces $55 Billion Investment in U.S. Manufacturing and Innovation
This major investment demonstrates J&J’s commitment to expanding its U.S. manufacturing and innovation capabilities, with potential benefits for job creation and the domestic pharmaceutical industry. The announcement aligns with broader trends of increased U.S. manufacturing investment by large corporations in recent years.
Viking Signs $150M Manufacturing Agreement with CordenPharma for Obesity Drug Candidate
Viking Therapeutics, CordenPharma, VK2735, obesity drug, manufacturing agreement, GLP-1/GIP dual agonist
Merck Opens $1 Billion Vaccine Manufacturing Facility in North Carolina
Merck, vaccine manufacturing, Durham, North Carolina, Gardasil, HPV vaccine, pharmaceutical industry, US manufacturing
Pfizer Prepared to Shift Manufacturing to US in Response to Potential Trump Tariffs
Pfizer, Albert Bourla, US manufacturing, Trump tariffs, pharmaceutical industry, reshoring
Pfizer’s European Manufacturing Vulnerable to Potential US Tariffs, CEO Warns
Pfizer, Albert Bourla, European manufacturing, US tariffs, pharmaceutical industry, trade tensions, supply chain disruption
Axplora Invests €50M in GLP-1 Manufacturing Expansion at Mourenx, France
Axplora, GLP-1, manufacturing expansion, Mourenx, France, CDMO, API production, chromatography, diabetes, obesity, biologic therapies
Turnstone Biologics Discontinues Final Clinical Program, Initiates Strategic Review Amid Financial Constraints
Turnstone Biologics, TIDAL-01, clinical program discontinuation, layoffs, strategic alternatives, TIL therapy, manufacturing costs, biotech industry challenges